Co-Bespres

Quick links to important sections

Co-Bespres

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Co-Bespres

Co-Bespres is a prescription-only medicine used to manage essential hypertension (high blood pressure). It is a fixed-dose combination (FDC) product that pairs two distinct, synthetic antihypertensive agents in a single oral tablet. This combination is intended to provide effective blood pressure control when monotherapy is inadequate.


Quick Facts

Property Description
Active Ingredients Valsartan and Hydrochlorothiazide (HCTZ)
Form Oral Tablet
Pharmacological Class Antihypertensive Agent (ARB and Thiazide Diuretic)
General Purpose To lower and control blood pressure
Origin Synthetic

What is Co-Bespres and What Class Does It Belong To?

Co-Bespres is classified as an Antihypertensive Agent. Its composition is key: Valsartan belongs to the Angiotensin II Receptor Blocker (ARB) class, which works to relax blood vessels, while Hydrochlorothiazide is a Thiazide Diuretic, which aids the body in reducing excess fluid volume. This specific pairing is one of several common ARB/Diuretic combinations used worldwide, with similar formulations marketed under names such as Co-Diovan and Diovan HCT.

The combination of these two components—an ARB and a diuretic—is indicated for the management of hypertension. This fixed combination is designed for use to achieve targeted blood pressure control, especially in adult patients diagnosed with primary (essential) hypertension.


Why Is a Combination Therapy Used for Hypertension?

The primary purpose of this combination therapy is to deliver a synergistic effect. This means the combined action of the two ingredients achieves a greater blood pressure reduction than could be achieved if either component were used alone. By intervening in both the hormonal system that controls vessel tension and the volume of fluid within the circulatory system, this approach provides a dual mechanism of action that blocks key contributors to elevated pressure. This strategy is a recognized approach for hypertension management.

Regulatory References

  1. Valsartan/Hydrochlorothiazide Drug Information

What side effects are possible with Co-Bespres?

Possible Side Effects and Safety Information

The safety profile of Co-Bespres (Valsartan/Hydrochlorothiazide) is formally categorized in regulatory documents, with adverse reactions grouped by frequency and affected body system.

Documented Adverse Reactions

Side effects are classified by their reported incidence in clinical trials. Common reactions (occurring in 1% to 10% of patients) include dizziness, headache, fatigue, and nasopharyngitis. Uncommon reactions may involve insomnia, cough, diarrhea, nausea, and muscle spasms.

Reactions are also grouped into System-Organ Classes, affecting systems such as the Nervous System and Gastrointestinal System. The diuretic component, hydrochlorothiazide (HCTZ), necessitates monitoring for Metabolism and Nutrition Disorders, specifically hypokalemia (low potassium) and hyperuricemia (high uric acid).

Serious Safety Considerations

Official labeling highlights several serious risks. The medication is contraindicated in the second and third trimesters of pregnancy due to the high risk of fetal injury and death. Other documented serious adverse events include Angioedema (rapid swelling), Acute Renal Failure, and Hepatic Failure.

Population and Exposure Constraints

The drug is contraindicated in patients with anuria (absence of urine production) and those with severe hepatic or severe renal impairment (creatinine clearance less than 30 mL/min). A time-related safety pattern notes that symptomatic hypotension may occur, particularly at the start of treatment. Additionally, the HCTZ component is associated with an increased risk of Non-Melanoma Skin Cancer (NMSC) with long-term exposure.

Overdose and Emergency Response

Overdose and when to seek help

Feature Official Regulatory Statement
Documented overdose presentations Overdose is primarily defined by profound hypotension (severe low blood pressure) and severe volume depletion resulting in electrolyte imbalance (e.g., low potassium or sodium levels). Heart rate changes, specifically tachycardia or bradycardia, may also be documented.
Physiological systems affected The principal physiological systems affected, as stated in regulatory documents, are the Cardiovascular system and the Fluid and Electrolyte Balance.
Population-specific overdose notes Official labeling notes an increased risk of severe complications, particularly from volume depletion and electrolyte disturbance, in individuals with impaired renal function.
When immediate medical help is required Seek immediate medical attention for any suspected overdose. Hospitalization and close medical supervision are required for patients who present with symptomatic overdose, such as signs of collapse or profound dizziness.

Overdose Classifications

Feature Official Regulatory Statement
Severity classification Overdose carries the risk of life-threatening consequences, including circulatory collapse (shock) and potentially cardiac arrhythmias secondary to critical electrolyte imbalances.
Antidote information No specific antidote is known for overdose involving the active components of this medicine.

Resulting Overdose Structure

Official overdose statements:

  • The primary documented manifestations are profound hypotension and severe volume depletion.
  • Management involves symptomatic and supportive treatment, including the required correction of fluid and electrolyte imbalances.
  • Procedures such as gastric lavage or activated charcoal may be officially considered in cases of recent ingestion.

Connection to the overall overdose profile: Regulatory documents strictly define the Co-Bespres overdose profile by the manifestations of severe blood pressure drop and fluid loss, which necessitate the explicit instruction to seek immediate medical attention. This foundation directs medical response toward supportive measures and monitoring of vital signs and serum electrolytes.

Therapeutic Uses of Co-Bespres

What Co-Bespres Treats: Main Uses and Benefits

Co-Bespres is a combination therapy indicated for the management of essential hypertension (high blood pressure) in adults whose condition is not adequately controlled by a single-component medication. The goal of managing this condition is to lower blood pressure, which in turn may assist with maintaining general well-being during symptomatic phases.

The medication is commonly used to help manage symptoms related to heightened physiological activity and systemic imbalance, particularly in clinical settings involving acute or unstable symptom patterns. Its application is relevant for easing discomfort when symptoms cluster into patterns requiring supportive management, and it assists with maintaining functional stability during phases when symptoms become more noticeable.

“The primary purpose of this combination is for use in clinical settings where long-term symptomatic assistance is appropriate.”

The therapeutic utility is applied across domains where short-term symptomatic assistance is needed and contributes to improved day-to-day comfort during symptomatic periods.

Quick Fact: Support for Heightened Symptoms
Co-Bespres is generally used in conditions characterized by periods of heightened physiological stress and helps ease the overall symptom burden.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Co-Bespres

Co-Bespres (Valsartan/Hydrochlorothiazide) is officially designated for use exclusively in adult patients diagnosed with essential hypertension. Official regulatory documents establish several absolute prohibitions and limitations that define who must not use the medicine.

Scope Regulatory Status
Absolute Contraindications The medicine is prohibited for pregnant women and must be discontinued immediately upon confirmed pregnancy. It is contraindicated for patients with hypersensitivity to any of its components or to sulfonamide-derived medicines.
Organ Function Prohibitions Use is strictly contraindicated in patients presenting with anuria, severe renal impairment (creatinine clearance le 30 mL/min), or severe hepatic impairment (including biliary cirrhosis or cholestasis).
Age and Comorbidity Rules Safety and efficacy have not been established in the pediatric population (below 18 years), and use is not recommended for this age group. Co-Bespres is also contraindicated in patients with diabetes mellitus who are receiving aliskiren for dual RAAS blockade.

Use Restrictions and Cautions: Use is not recommended for nursing mothers (lactation). Patients with mild to moderate hepatic impairment or intravascular volume depletion are eligible only with specific regulatory precautions and the potential correction of the underlying condition before treatment initiation.

What should I know about interactions with other medicines?

Co-Bespres has officially documented interaction patterns primarily concerning its effects on the renin-angiotensin system, electrolyte balance, and substance clearance. The product's regulatory profile delineates specific restrictions for co-administration.

Contraindicated Combinations and Key Restrictions

Co-administration with Aliskiren is formally contraindicated in patients with diabetes or moderate-to-severe renal impairment, due to the increased risk of hypotension, hyperkalemia, and worsening renal function. The medicine is also contraindicated in patients with anuria or known sulfonamide hypersensitivity.

Clinically Significant Interactions

Interactions involving electrolyte balance and renal function are officially noted. Co-use with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may increase the risk of renal function deterioration and may reduce the medicine's antihypertensive and diuretic effects. Additive effects on serum potassium are documented when Co-Bespres is used concurrently with potassium-sparing diuretics or potassium supplements, increasing the risk of hyperkalemia. The hypotensive effects of Co-Bespres may also be potentiated by alcohol or other blood pressure-lowering agents.

Exposure Modification and Timing Rules

Hydrochlorothiazide officially reduces the renal clearance of Lithium, documented to result in an increased risk of toxicity, which necessitates monitoring. The absorption of the diuretic component is reduced by Cholestyramine or Colestipol. Co-Bespres must be administered at least 4 to 6 hours before, or 4 hours after these bile acid sequestrants. Co-administration of the OATP1B1 inducer Apalutamide is also noted to decrease the systemic exposure of the Valsartan component.

Mechanism of Action

How Co-Bespres Works

Co-Bespres exerts its action through a combination of two distinct mechanisms, targeting two fundamental physiological pathways: vessel tension and fluid volume regulation.


️ Angiotensin II Receptor Blockade and Vascular Relaxation

This mechanism is driven by Valsartan, which functions as a selective antagonist on the Angiotensin II Receptor Type 1 (AT1 Receptor). By preventing the potent vasoconstrictor Angiotensin II from binding to the AT1 receptor, the drug suppresses the signaling cascade that causes blood vessels to constrict. This antagonism leads directly to vasodilation and a reduction in systemic vascular resistance.


Inhibition of Renal Salt and Volume Reabsorption

Hydrochlorothiazide (HCTZ) modulates fluid volume by inhibiting the Sodium Chloride Cotransporter (NCC) in the kidney's distal convoluted tubule. This inhibition prevents the reabsorption of sodium and chloride ions from the forming urine back into the bloodstream. The resulting increase in salt and water excretion (diuresis and natriuresis) leads to a reduction in the total circulating plasma volume.


Synergistic Neutralization of Compensatory Responses

The mechanisms are synergistically coupled: the HCTZ-induced volume loss activates the body’s homeostatic RAAS system. Valsartan's AT1 blockade prevents this compensatory activation from functionally limiting the volume-reducing mechanism. The resulting simultaneous, dual-pathway physiological modulation of reduced resistance and reduced volume affects systemic pressure.

Dosage and Administration Information

How to Use Co-Bespres

The administration of Co-Bespres, a fixed-dose combination of Valsartan and Hydrochlorothiazide, is based on standard clinical guidelines.

Administration Scope: General Guidelines

Instruction Detail
Route of administration: Oral use only.
Dosing schedule (Adult): Initial dose is typically 160/12.5 mg once daily. The dose can be increased after 1 to 2 weeks of therapy as needed.
Maximum Recommended Dose: 320/25 mg (Valsartan/HCTZ) once daily.
Timing in relation to meals: May be taken with or without food.
Age-group restrictions: Not recommended for use in children or adolescents under 18 years of age.
Special procedural conditions: The tablet must be swallowed whole with some liquid; use is not recommended in patients with severe renal impairment (creatinine clearance < 30 mL/min).

Use Protocol and Dosing Titration

Co-Bespres is designed for a once-daily dosing frequency. The dosage is initiated at a lower strength and maintained for a period of one to two weeks before any dose adjustment is considered. This titration period allows for the assessment of the antihypertensive effect, which is generally attained within two to four weeks after a change in dose.

For patients with mild to moderate hepatic impairment, the dose for the Valsartan component should not exceed 80 mg. No special initial dosage adjustment is required for older adults. The primary administration rule is to take the medicine at the same time each day to maintain consistent control.

These standardized instructions define the clinical use of the medicine, and correspond to the frequency, administration route, and maximum dose limits.

Recent Clinical Evidence

Research evidence / Overview of studies for Co-Bespres

Evidence for Use in Essential Hypertension

Research examining the use of Co-Bespres (valsartan and hydrochlorothiazide combination) has focused primarily on its application for essential hypertension (high blood pressure) and observing blood pressure measurements when control is not achieved with a single medicine. The initial evidence was derived from short-term, randomized controlled trials (RCTs). These studies were designed to compare the combination tablet against a placebo and against each of the individual ingredients used alone. This factorial design approach helps researchers understand the comparison against its components.

The main measures that researchers monitored in these pivotal studies were blood pressure readings, specifically tracking the mean sitting Systolic and Diastolic Blood Pressure. Studies monitored the response over defined time intervals, typically 8 to 12 weeks. Findings described patterns observed where the proportion of participants achieving specific blood pressure measurements was tracked when using the two-ingredient combination compared to using just one ingredient. This combination was studied for its effect in patient groups that included those whose hypertension was already established and those whose condition was considered mild to severe.

Study Design and Comparison Groups

Studies explored how the combination was evaluated by tracking specific measurements like 24-hour Ambulatory Blood Pressure Monitoring (ABPM) readings. Research examined the use of the medicine in populations where blood pressure control was considered inadequate under monotherapy. These comparisons provide context but not individual predictions, helping to show what has been observed so far under specific, controlled study conditions. The findings help contextualize how the combination was evaluated against the individual components and a placebo across the defined study periods.

Long-term Follow-up and Durability of Study Data

To understand how longer-term follow-up was addressed over extended time frames, research has examined data structures beyond the initial short-term trials. Follow-up durations were limited in the primary regulatory studies, which focused on the initial change in blood pressure. However, some open-label extension studies and post-marketing surveillance (PMS) data tracked patient groups for up to one to five years. These longer-term observational settings evaluating daily-life functioning have been used to monitor patient reports and physiological strain in a variety of clinical settings over time. Research provides insight into the long-term context of using this therapeutic strategy, but this evidence is primarily observational compared to the short-term RCT data.

Research in Specific Patient Groups

Studies have been conducted to understand the evidence for the use of the combination in specific patient subgroups. Research has described patterns related to blood pressure readings in older adults (aged 70 and over) and in patients with co-existing conditions, such as diabetes or high cholesterol (hyperlipidemia). The results apply only to the populations studied, and data for certain groups, such as children, remain limited. Evidence contributes to understanding symptom patterns, but findings were sometimes mixed or limited when isolating the effects in very specific, small subgroups.

Key Limitations and Areas of Ongoing Research

While the initial studies provide data related to short-term blood pressure measurements, certain aspects of the medicine’s long-term utility remain uncertain. The most noted research limitation frames the fact that there are no controlled trials specifically designed and powered to directly track the prevention of major cardiovascular events, such as heart attack or stroke, with the use of this fixed-dose combination compared to other therapeutic options. Long-term effects on these vital outcomes are not fully established. Therefore, the evidence quality varies across studies, and limited information is available for certain long-term outcomes, particularly those derived from trials designed to track serious health events over many years.

Key Studies & References Label: VALSARTAN AND HYDROCHLOROTHIAZIDE tablet, film coated (DailyMed/FDA Monograph for core evidence and long-term trial status)

Frequently Asked Questions (FAQ)

Common questions about Co-Bespres (FAQ)


Q: How long does it usually take for Co-Bespres to start working?

A: According to official product information, while an initial blood pressure reduction may occur sooner, the maximum blood pressure-lowering effect is generally reached within two to four weeks after starting the medicine or after a dose change. Patients are generally advised to continue their medication regimen as prescribed during this initial period.


Q: Is it normal to feel dizzy when first starting Co-Bespres?

A: Yes, regulatory documents indicate that dizziness is a common side effect. It is noted that a drop in blood pressure that causes symptoms, known as symptomatic hypotension, may happen, especially when a patient first begins treatment. Persistent or severe dizziness is a symptom that should be discussed with a healthcare provider.


Q: Can Co-Bespres be taken with food, or should it be on an empty stomach?

A: Official prescribing information states that Co-Bespres may be taken with or without food. Taking it with a meal or on an empty stomach does not affect how the medicine works overall.


Q: What happens if I accidentally miss a dose of Co-Bespres?

A: Official patient information outlines a general protocol: a missed dose may be taken as soon as it is remembered. However, if the time for the next scheduled dose is near, the protocol is typically to skip the missed dose and resume the regular schedule. Taking two doses at once is generally not recommended.


Q: Is it safe to drink coffee while taking Co-Bespres?

A: There is no specific interaction formally documented in regulatory labels between Co-Bespres and caffeine or coffee. However, it is important to remember that caffeine can temporarily raise blood pressure, and patients are typically cautioned about the combination of this medicine with other substances that lower blood pressure, such as alcohol.


Q: Can Co-Bespres affect my blood sugar levels?

A: Yes, the Hydrochlorothiazide component of the medicine may cause an increase in blood sugar (glucose) levels. Official guidelines state that for patients with diabetes, closer monitoring of blood sugar levels may be necessary due to the HCTZ component.


Q: What are the signs that Co-Bespres might not be working for me?

A: The effectiveness of Co-Bespres is monitored by a healthcare provider through blood pressure measurements. If desired blood pressure goals are not achieved after a period of therapy, the doctor may consider adjusting the dose. Any concerns about the medication’s effectiveness or a lack of desired blood pressure reduction should be reviewed with the prescribing physician.


Q: Are there known interactions between Co-Bespres and herbal supplements?

A: Official drug labels mainly list interactions with other prescription drugs and supplements that affect potassium levels. They do not provide a comprehensive list of every possible herbal supplement. Patients are generally advised to inform their healthcare provider about all supplements, including herbal products, being used.


Q: Can Co-Bespres cause muscle cramps or spasms?

A: Regulatory documents list muscle spasms as an uncommon adverse reaction associated with Co-Bespres. Furthermore, potential symptoms of an electrolyte imbalance caused by the diuretic component can sometimes include symptoms like muscle weakness or pain.


Q: What should I do if my blood pressure is still high after starting Co-Bespres?

A: Concerns regarding sustained high blood pressure should be addressed through follow-up with a healthcare provider. The dose is typically evaluated and adjusted by a healthcare provider after one to two weeks of therapy. Any concerns regarding the medication’s efficacy are typically discussed with the prescribing physician.


Q: Are there different strengths available for Co-Bespres tablets?

A: Yes, official regulatory information confirms the combination of Valsartan and Hydrochlorothiazide is manufactured and available in multiple different dosage strengths. This allows healthcare providers to select the appropriate combination for patients.


Q: What is the expected duration of action for one dose of Co-Bespres?

A: Co-Bespres is designed for a once-daily dosing frequency. This means it is formulated and intended to provide effective and consistent blood pressure control throughout a full 24-hour period after administration.


Q: Why do some people experience changes in urination frequency with Co-Bespres?

A: The 'Co-' part of the medicine name includes Hydrochlorothiazide, which is a diuretic, often called a 'water pill.' This drug works by increasing the body’s excretion of salt and water through the kidneys, which is why some patients may notice an increase in how often they need to urinate.


Q: What are the signs of a serious side effect from Co-Bespres?

A: Official labeling highlights certain serious risks that require immediate medical attention. These include signs of an allergic reaction like angioedema (swelling of the face, lips, tongue, or throat). Furthermore, the medicine is contraindicated in the second and third trimesters of pregnancy due to the high risk of fetal injury.


Q: Can Co-Bespres be taken with aspirin or NSAIDs?

A: Regulatory information indicates that co-use of the medicine with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may increase the risk of renal function deterioration. This combination may also potentially reduce the blood pressure-lowering effect of Co-Bespres.


Q: Is Co-Bespres used to prevent stroke or heart attack?

A: Co-Bespres is officially indicated for the treatment of high blood pressure, which is a known risk factor for cardiovascular events like heart attack and stroke. However, regulatory documents state that no controlled clinical trials have been conducted using the combination specifically to track the direct prevention of these major cardiovascular events.


Q: Is it okay to take multivitamins while using Co-Bespres?

A: All supplements should be reviewed with a healthcare provider. Taking Co-Bespres with certain supplements, particularly those containing high amounts of potassium, may increase the risk of hyperkalemia (high potassium levels). Official product information specifically warns against taking potassium-sparing diuretics or potassium supplements concurrently.


Q: Are generic versions of Co-Bespres available, and are they the same?

A: Yes, generic versions of the combination drug are approved and available. Generic products are required by the FDA to demonstrate bioequivalence to the brand-name product, meaning they deliver the same amount of active ingredient into the bloodstream in the same amount of time.


Q: Do people need to take potassium supplements with Co-Bespres?

A: The Hydrochlorothiazide component can sometimes cause hypokalemia (low potassium), but regulatory warnings note that taking the drug with potassium supplements may also cause hyperkalemia (high potassium) due to the Valsartan component. Potassium levels are typically managed and monitored by a healthcare professional.


Q: What's the difference between Co-Bespres and just Bespres?

A: The name Co-Bespres implies a combination therapy. Regulatory labeling shows that it contains two active ingredients: Valsartan and Hydrochlorothiazide. The name Bespres (or the monotherapy version) contains only Valsartan.


Q: What are the ingredients in Co-Bespres that treat edema (swelling)?

A: The Hydrochlorothiazide component is the ingredient responsible for fluid-related effects. As a diuretic, it helps the body reduce excess fluid volume by increasing salt and water excretion, which can help reduce swelling caused by fluid retention.


Q: Does Co-Bespres make you tired or lethargic?

A: Official safety documents list fatigue as a common side effect of Co-Bespres. Furthermore, symptoms related to potential electrolyte imbalances can include feelings of drowsiness and a general lack of energy or lethargy.


Q: Can Co-Bespres cause sensitivity to the sun?

A: Yes, the Hydrochlorothiazide component is associated with an increased sensitivity to sunlight, known as photosensitivity. Long-term exposure to this component is also linked to an increased risk of Non-Melanoma Skin Cancer (NMSC), according to official warnings.


Q: What class of drug does the 'co' part belong to?

A: In pharmaceutical naming, the 'Co-' prefix often signals a combination product or 'co-formulation.' In this case, it specifically refers to the combination of Valsartan with Hydrochlorothiazide (HCTZ), which belongs to the class of Thiazide Diuretics.

How should Co-Bespres be stored and disposed of?

How to Store and Dispose of Co-Bespres

The storage and disposal requirements for Co-Bespres (valsartan and hydrochlorothiazide) are set by regulatory agencies to ensure the medicine's stability and safety.

Co-Bespres tablets must be stored at Controlled Room Temperature, typically defined as 20 C to 25 C (68 F to 77 F). The medication must be protected from moisture and light and should be kept in a closed, light-resistant container to prevent degradation. It is mandatory to store the medicine out of the reach of children and to keep it from freezing or excessive heat.

Expired or unused tablets must be handled as pharmaceutical waste. Official instructions state that the product should be disposed of according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Co-Bespres found in:

A-Z Index: